Klomipramin Mylan 25 mg Norge - norsk - Statens legemiddelverk

klomipramin mylan 25 mg

mylan ab - klomipraminhydroklorid - tablett, filmdrasjert - 25 mg

Klomipramin Mylan 10 mg Norge - norsk - Statens legemiddelverk

klomipramin mylan 10 mg

mylan ab - klomipraminhydroklorid - tablett, filmdrasjert - 10 mg

Protaminsulfat LEO Pharma 1400 anti-heparin IE/ ml Norge - norsk - Statens legemiddelverk

protaminsulfat leo pharma 1400 anti-heparin ie/ ml

leo pharma (2) - protaminsulfat - injeksjons-/infusjonsvæske, oppløsning - 1400 anti-heparin ie/ ml

Vitamin K2 kapsler Norge - norsk - myHealthbox

vitamin k2 kapsler

tg mongomery - vitamin k2 - kapsler - magnesium stearate (e 470b), maltodekstrin, microcrystalline cellulose (e 460), trikalsiumfosfat

Incivo Den europeiske union - norsk - EMA (European Medicines Agency)

incivo

janssen-cilag international n.v. - telaprevir - hepatitt c, kronisk - antivirale midler til systemisk bruk - incivo, i kombinasjon med peginterferon alfa og ribavirin, er indisert for behandling av genotype-1, kronisk hepatitt c hos voksne pasienter med kompensert leversykdom (inkludert skrumplever):hvem er behandling naiv, som tidligere har vært behandlet med interferon alfa (pegylated eller ikke-pegylated) alene eller i kombinasjon med ribavirin, inkludert relapsers, delvise besvarelser og null-respondere.

Blincyto Den europeiske union - norsk - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - forløpercellelymfoblastisk leukemi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Aminess 70 mg / 45 mg / 60 mg / 90 mg / 65 mg / 90 mg / 65 mg / 25 mg / 75 mg / 135 mg Norge - norsk - Statens legemiddelverk

aminess 70 mg / 45 mg / 60 mg / 90 mg / 65 mg / 90 mg / 65 mg / 25 mg / 75 mg / 135 mg

meda as - fenylalanin / histidin / isoleucin / leucin / lysinacetat / metionin / treonin / tryptofan / tyrosin / valin - tablett, filmdrasjert - 70 mg / 45 mg / 60 mg / 90 mg / 65 mg / 90 mg / 65 mg / 25 mg / 75 mg / 135 mg

Elvanse 30 mg Norge - norsk - Statens legemiddelverk

elvanse 30 mg

takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 30 mg

Elvanse 20 mg Norge - norsk - Statens legemiddelverk

elvanse 20 mg

takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 20 mg

Elvanse 40 mg Norge - norsk - Statens legemiddelverk

elvanse 40 mg

takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 40 mg